CDKN2A and neoplasm: Using CRISPR/Cas9, we generated a spectrum of mutation combinations (PT: PTEN-/-; TP53-/-, PTCC: PTEN-/-; TP53-/-; CDKN2A-/-; CDKN2B-/-, PTN: PTEN-/-; TP53-/-; NF1-/-), which are among the most frequently mutated tumor suppressors in GBM patients5, in two iPSCs derived from healthy donor, one cell line expressing GFP.